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The use of vitamin C against different diseases has been
controversially and emotionally discussed since Linus
Pauling published his cancer studies. In vitro and animal
studies showed promising results and explained the
impact of vitamin C, particularly in cases with endothelial
dysfunction. Indeed, studies (reviewed in this issue of
Critical Care by Oudemans-van Straaten and colleagues)
using high-dose vitamin C and the parenteral route of
application seem to be more successful than oral vitamin
C delivery.oxygen species. Furthermore, as vitamin C is necessaryEndothelial dysfunction (ED) – as a pathology emerging,
for example, out of surgery-elicited ischemia–reperfusion
injury or arising during sepsis – contributes to tissue injury,
thereby promoting the development of multiple organ
failure [1] and as a consequence elevating the length of hos-
pital stay and costs. To deal with this challenging situation,
antioxidant therapy – in particular, the use of vitamin C –
has been frequently recommended and is under continuous
controversial discussion. In this issue of Critical Care,
Oudemans-van Straaten and colleagues give an overview of
the current experimental and clinical data for vitamin C in
this context [2].
The pathophysiological situation of ED – including
impaired regulation of vascular tone, compromised endo-
thelial barrier function and loss of the endothelium’s anti-
thrombotic and antiatherogenic properties [3] – is mainly
caused by two highly connected mechanisms: the loss of
nitric oxide (NO) availability and function; and the highly
increased production of reactive oxygen species, especially
superoxide and peroxynitrite. Both of these mechanisms re-
sult from an uncoupling of endothelial nitric oxide synthase
(eNOS) that occurs when tetrahydrobiopterin, a cofactor of* Correspondence: hans-K.biesalski@uni-hohenheim.de
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(http://creativecommons.org/publicdomain/zeroeNOS, is not sufficiently available. In this uncoupled state,
eNOS produces superoxide instead of NO (for a compre-
hensive review, see [4]). Furthermore, the accompanying in-
flammation leads to the activation of NADPH oxidase and
inducible NO synthase, producing high amounts of super-
oxide and NO, respectively, thereby further promoting the
formation of peroxynitrite.
Vitamin C can ameliorate this situation by different
methods of action (reviewed in detail in [2]). First, vitamin
C inhibits the activation of NADPH oxidase and inducible
NO synthase, as shown both in vitro and in animal
models, thereby preventing the formation of reactive
for the reductive recycling of tetrahydrobiopterin, it coun-
teracts the uncoupling of eNOS, thereby contributing to
the recovery of endothelial function.
Interestingly, although there is consensus concerning
the approach of reversing uncoupled eNOS via provision
of tetrahydrobiopterin to combat ED [4,5], vitamin C seems
not to be considered as a therapeutic option. This might be
due to some contradictory results concerning the impact of
vitamin C in the setting of vascular oxidative stress, ranging
from beneficial effects in small clinical studies (reviewed
in [2]) to no effect in a large-scale randomized clinical trial
[6]. This latter result might have given the temporary
deathblow to vitamin C for ED therapy.
However, high-dose vitamin C administration – a phrase
frequently occurring in the review [2] – cannot be achieved
with oral application. Indeed, as Padayatty and coworkers
showed in their investigation of vitamin C kinetics, most
notably it is the route of vitamin C administration that has
to be taken into account [7]. As the intestinal absorption
for vitamin C is rapidly saturated, high dosages of vitamin
C (>500 mg) have to be applied intravenously and not via
the oral route, as practiced [6]. The failure of that study to
show an effect is simply that the investigators chose the
wrong route of application.
In fact, there are two reasons to administer vitamin C
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surgery.
Indeed, the results of several clinical investigations
in patients undergoing cardiac surgery with use of car-
diopulmonary bypass – the latter necessarily evoking
ischemia–reperfusion injury – showed a strong and long-
lasting decrease in vitamin C plasma concentrations fol-
lowing surgery [8,9]. Furthermore, Cowley and coworkers
demonstrated a positive relationship between plasma
antioxidant potential and survival rate in patients with
severe sepsis [10]. Supplementation of vitamin C in patients
undergoing any surgery eliciting ischemia–reperfusion
injury or suffering sepsis therefore seems to be highly
recommendable.
For reconstitution of adequate vitamin C plasma levels
in critically ill patients, high doses of vitamin C (3 g/day)
given intravenously for 3 days or more are needed [11].
An argument against the high-dose application was the
risk of an increased formation of vitamin C radicals. How-
ever, in a study with healthy volunteers we showed that
parenteral vitamin C (750 or 7,500 mg for 6 consecutive
days) does not lead to any pro-oxidative effects [12].
We need to consider that intravenous application of
vitamin C has nothing to do with the known physiology
of vitamin C from nutrition or oral supplements. Circum-
venting the physiological control of vitamin C following
oral intake may lead to very different effects that may
be distinct from those we know from nutrition studies.
Parenteral application is a pharmacological approach.
Indeed, little is known about the distribution, metabolism,
action and degradation as well as the optimal moment
and time course for intravenous high-dose supplementa-
tion of vitamin C in the context of ED.
Controlled studies are needed to elucidate whether
early high-dose administration of vitamin C might help
to keep the plasma level in a normal range and to
prevent ED.
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